Innate Pharma S.A.

The company did not report revenue, EPS, or gross margin on this call. It ended the quarter with a cash position of EUR 25.4 million as of March 31, 2026. For guidance, management expects TELLOMAT-3 lacutamab Phase III initiation in the second half of 2026, IPH4502 clinical data to be presented at a medical conference before year-end, and PACIFIC-9 data in the second half of 2026. Management also said a lacutamab partnership or royalty financing could be concluded in the relatively short term, potentially before Q3.

Jonathan Dickinson framed the quarter as steady execution against a focused strategy centered on three priority assets. He highlighted regulatory progress for lacutamab, early clinical signal for IPH4502, and completed enrollment for PACIFIC-9, presenting the portfolio as a set of near-to-medium-term value catalysts. His tone was constructive but cautious, repeatedly tying next steps to financing discipline and upcoming data.

No formal quarter income statement details were given on the call, but management did discuss balance-sheet and funding priorities. Jonathan Dickinson said the company had EUR 25.4 million of cash at March 31, 2026 and emphasized disciplined execution. On funding, management said lacutamab is being advanced with non-dilutive options such as pharma partnerships and royalty-based structures, while the AstraZeneca programs should continue to provide milestone, royalty, and profit-sharing potential; they also said AstraZeneca contributions on PACIFIC-9 are very close to the cap, leaving minimal contributions needed before readout.

Analysts pressed on whether the MATIS CD39/IPH5201 interim data is truly differentiated versus prior durvalumab/chemo benchmarks; management said the signal looks promising because it appears to improve pathological complete response without adding toxicity, but they acknowledged they cannot predict Phase III outcomes. Questions on IPH4502 focused on the go-forward dose, other indications, and competition; management said they would disclose more at a medical conference later this year, including data in urothelial cancer and next steps. On lacutamab, management said partnership discussions are advanced and they expect to finalize either a business-development deal or royalty financing in the relatively short term, potentially before Q3, while PTCL data timing remains uncertain because that study is run by an external group.